Gland Pharma Limited

Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. It manufactures a diversified range of high-quality complex injectables. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc.
The company follows a B2B model to sell its products in more than 60 countries including the US, Canada, Australia, India, Europe, etc. Leading pharma companies i.e. Sagent Pharmaceuticals, Apotex Inc. Athnex Pharmaceutical Division, LLC, Fresenius Kabi USA, LLC, etc. are some of the key customers.
It has 7 robust manufacturing units in India comprising 4 finished formulations facilities, 22 production lines, and 3 APIs.

Company Strengths

The extensive product portfolio of complex injectables.
Diversified B2B model with a targeted B2C model in India.
Strong manufacturing capabilities.
Robust financial track record.
Experienced and qualified managerial team.

Gland Pharma IPO Details

Issue TypeBook Built Issue IPO
Face Value₹1 per equity share
IPO Price₹1490 to ₹1500 per equity share
Market Lot10 Shares
Min Order Quantity10 Shares
Listing AtBSE, NSE
BSE Script Code543245
NSE SymbolGLAND
ISININE068V01023
Issue SizeAggregating up to ₹6,479.55 Cr
Fresh IssueAggregating up to ₹1,250.00 Cr
Offer for SaleAggregating up to ₹5,229.55 Cr

Gland Pharma IPO Tentative Timetable

PARTICULARDATE
IPO Open Date9-Nov-20
IPO Close Date11-Nov-20
Basis of Allotment Date17-Nov-20
IPO Listing Date20-Nov-20

Gland Pharma IPO Lot Size

ApplicationLotsSharesAmount (Cut-off)
Minimum110₹15,000
Maximum13130₹195,000

IPO Allotment Status

please click hare to check IPO Allotment Status For Gland Pharma Limited

Company Financials:

 PARTICULAR 30-Jun-2031-Mar-2031-Mar-1931-Mar-18
Total Assets46,912.6540,860.3935,235.4929,294.68
Total Revenue9,162.8927,724.0821,297.6716,716.82
Profit After Tax3,135.907,728.584,518.563,210.51
For the year/period ended (Rs in million)

Company Promoters:

Fosun Pharma Industrial Pte. Ltd and Shanghai Fosun Pharmaceutical (Group) Co. Ltd is the company promoters.

Objects of the Issue:

The net proceeds from the IPO will be used for the following purposes:

  1. To finance the incremental working capital requirements of our Company
  2. To meet funding requirements for capital expenditure requirements
  3. To meet the general corporate purposes

Registrar & Company Details

Company Contact InformationGland Pharma IPO Registrar
Gland Pharma Limited
Sy. No. 143 – 148, 150 and 151,
Near Gandi Maisamma ‘X’ Roads, D.P. Pally,Dundigal
Medchal-Malkajgiri District, Hyderabad
Phone: +91 40 3051 0999
Email: investors@glandpharma.com
Website: http://www.glandpharma.com
Link Intime India Private Ltd
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai – 400083
Phone: +91-22-4918 6270
Email: glandpharma.ipo@linkintime.co.in
Website: http://www.linkintime.co.in

Related posts

Leave a Comment